ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 5
Optimizing Bridging Therapies and Post–CAR T Approaches
Panelists discuss the impact of blinatumomab’s FDA approval on sequencing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (R/R ALL), the use of bridging therapies prior to CAR T infusion, and approaches to consolidation or maintenance treatment following CAR T therapy.
Video Player is loading.
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Molina: With blinatumomab’s FDA approval in the earlier-line setting in ALL, does this impact how you sequence CAR-T cell therapy for your R/R ALL patients?
- Dr. O’Dwyer to Dr. Shaughnessy: In real-life day-to-day practice, how often are you utilizing bridging therapy prior to CAR T cells, and what agents are you typically using? What is the role of bridging therapies prior to CAR T cells being infused?
- Resource link: Park JH et al. Bridging therapies FELIX study. ASH 2024 poster abstract or see Appendix 6
- Dr. O’Dwyer to Dr. Logan (then open to panelists): What is your consolidation or maintenance treatment approach post CAR T-cell therapy? Can CAR T-cell therapy be a stand-alone therapy?
